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Abstract
Background: The aim was to assess the influence of long-term treatment with tumor necrosis factor alpha (TNF-α)
inhibitors on total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL),
and atherogenic index (AI) in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) patients.
Methods: A retrospective cohort study was conducted on RA, PsA, and AS patients treated with TNF-α inhibitors for at
least 270 days between 2001 and 2011. Levels of TC, TG, LDL, and HDL and the AI were compared with baseline values
at 0–6, 6–12, 12–18, and 18–24 months. Patients were further subdivided into three groups according to their HMG
CoA reductase inhibitor (statin) treatment status in order to assess their effect on the results.
Results: The records of 311 patients (152 RA, 90 PsA, and 69 AS) were reviewed. TC and TG increased following
treatment with TNF-α inhibitors, from 180.85 ± 2.12 mg/dl and 116.00 ± 3.55 mg/dl at baseline to 188.12 ± 2.35 mg/dl
(p = 0.02) and 132.02 ± 4.63 mg/dl at 0–6 months (p < 0.01), respectively, and to 184.88 ± 2.09 mg/dl (p = 0.02) and 129.
36 ± 4.32 mg/dl at 18–24 months (p < 0.01), respectively. AI increased following treatment with TNF-α inhibitors, from –
0.032 ± 0.017 at baseline to 0.004 ± 0.019 at 18–24 months (p < 0.01). LDL decreased significantly in patients who were
treated with statins before and during the entire study period, from 119.97 ± 2.86 mg/dl at baseline to 104.02 ± 3.57
mg/dl at 18–24 months (p < 0.01), in contrast to an increase in LDL values in patients who did not receive statins
during the study.
Conclusions: TNF-α inhibitor treatment was associated with a significant increase in TC and TG levels and the AI.
Adding statins to the treatment was associated with a significant decrease in LDL levels.
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Background
Atherosclerosis is a major cause of morbidity and mor-
tality in systemic autoimmune diseases. Inflammation is
central to the pathogenesis of atherosclerosis and is an
important risk factor for vascular disease [1]. An increase
in the atherogenic index (AI) is associated with an in-
crease in the atherosclerosis process [2]. It is therefore im-
portant to treat cardiovascular risk factors, including
dyslipidemia, in these patients.
The influence of tumor necrosis factor alpha (TNF-α)
inhibitors on lipid profile [3–17] and AI [3, 5, 7–9, 11,
13, 14, 17] in patients with rheumatologic diseases has
been examined in several studies (Table 1), with incon-
sistent results. In some studies TNF-α inhibitors promoted
an atherogenic lipid profile, while in others there was
no such effect. None of the studies assessed the time-
dependent impact of TNF-α inhibitors on the lipid pro-
file of ankylosing spondylitis (AS), psoriatic arthritis (PsA),
and rheumatoid arthritis (RA) patients as a group.
Our objective was to assess the influence of TNF-α
inhibitors treatment on the lipid profile and the AI of
patients with AS, PsA, and RA at various time points
up to 2 years of treatment.
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A retrospective cohort analysis was conducted on the
database of Clalit Health Services (CHS) in Haifa and
Western Galilee districts in northern Israel. CHS is the
biggest healthcare provider in Israel, with over 1 million
members in this area (approximately 50 % of the total
population of the region). CHS maintains a comprehen-
sive computerized database with continuous input from
pharmaceutical, medical, laboratory, and administrative
computerized operators. The CHS database and our study
cohort were described in a previous study [18]. Briefly, the
database for biological agents included in the Israeli
‘health basket’ contains diagnoses of specific rheumatic
diseases as determined by a rheumatologist. The data are
linked through a unique national identification number to
the pharmaceutical, medical, and laboratory databases.
Medical charts of patients who met the following cri-
teria were reviewed: minimum 18 years old; diagnosis
under one of the codes—‘rheumatoid arthritis’, ‘psoriatic
arthritis’, and ‘ankylosing spondylitis’—and approval for
biologic treatment included in the Israeli health basket;
treated with TNF-α inhibitors between 2001 and 2011;
began TNF-α inhibitors during the study period and
were treated for at least 270 consecutive days; and had
baseline lipid levels measured before starting treatment
with TNF-α inhibitors and at least three lipid profile
tests during the four time periods (0–6 months, 6–12
months, 12–18 months, and 18–24 months) (Fig. 1).
The following data were collected: demographics (age,
gender); rheumatologist diagnosis (RA, PsA, AS); comor-
bidities (diabetes, hypertension, hyperlipidemia, ischemic
heart disease); type and dates of pharmacy-dispensed medi-
cation (TNF-α inhibitors, steroids, disease-modifying
anti-rheumatic drugs (DMARDs), HMG CoA reductase
inhibitors (statins), fibrates); diabetes treatment; and la-
boratory tests results—lipid profile that included total
cholesterol (TC), triglycerides (TG), low-density lipo-
protein (LDL), and high-density lipoprotein (HDL). AI
was calculated by the following formula: AI = log (TG/







Disease Drug Research type TCa TGa LDLa HDLa AIa
Popa et al. [4] 2005 The Netherlands 2 33 RA ADA Prospective ↑ ↔ ↔ ↑
Vis et al. [6] 2005 The Netherlands 6 69 RA INF Prospective ↑ ↑
Seriolo et al. [8] 2006 Italy 24 34 RA ETA, ADA,
INF
Prospective ↑ ↔ ↑ ↔
Allanore et al. [10] 2006 France 30 56 RA INF Prospective ↑ ↑ ↑
Popa et al. [9] 2007 The Netherlands 52 55 RA INF Prospective ↑ ↑ ↔ ↔ ↑
Tam et al. [11] 2007 China 14 19 RA INF Prospective ↑ ↑ ↑ ↑ ↔
Peters et al. [13] 2007 The Netherlands 48 80 RA INF Prospective ↔ ↔ ↔ ↔
Wijbrandts et al. [16] 2009 The Netherlands 52 50 RA ADA Prospective ↔ ↔ ↔ ↔
Mathieu et al. [7] 2010 France 14 34 AS ETA, ADA,
INF
Prospective ↑ ↔ ↔ ↑ ↔
Castro et al. [12] 2011 Brazil 3 15 PA INF Prospective ↔ ↑ ↔ ↔




↑ ↑ ↔ ↑ ↔
Curtis et al. [5] 2012 United States Median >
2 years
289 RA TNFi Retrospective ↑ ↑ ↑ ↑ ↔
Di Minno et al. [14] 2014 2–52 1707 RA TNFi Meta-analysis ↑ ↑ ↔ ↑ ↔
30 articles PsA
AS
Souto et al. [15] 2015 12–24 25 articles RA ADA, INF Systematic review,
meta-analysis
↔ ↔ ↔ ↔
Chen et al. [25] 2015 Taiwan 24 48 RA ETA, ADA Prospective ↔ ↔ ↔ ↑ ↔
Present study 2016 Israel 104 311 RA TNFi Retrospective ↑ ↑ ↔ ↔ ↑
PsA
AS
aOnly significant changes (p ≤ 0.05) at the end of the follow-up period were included
TNF-α tumor necrosis factor alpha, TC total cholesterol, TG triglycerides, LDL low-density lipoprotein, HDL high-density lipoprotein, AI, atherogenic index,
RA rheumatoid arthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, ADA adalimumab, INF infliximab, ETA etanercept, TNFi TNF inhibitors
↑ Increased, ↔ Unchanged
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HDL), with TG and HDL expressed in molar concen-
trations [2].
The patients were subdivided into three groups ac-
cording to statin treatment:
Group 1 Patients not treated with statins.
Group 2 Patients who started statin therapy during the
study period, after the initiation of treatment
with TNF-α inhibitors.
Fig. 1 Study flow. TNF-α tumor necrosis factor alpha, TC total cholesterol, TG triglycerides, LDL low-density lipoprotein, HDL high-density lipoprotein,
RA rheumatoid arthritis, AS ankylosing spondylitis, PsA psoriatic arthritis
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Group 3 Patients who were treated with statins prior
to and during the entire study period.
Patients from Groups 2 and 3 were included only if
the type and dose of statin did not change during the
study period. Patients treated with fibrates, which are
known to reduce TG levels [19], were excluded from the
analysis in the TG group.
Statistical methods
Descriptive statistics are presented with continuous vari-
ables expressed as mean or median and standard deviation
or standard error and categorical variables as frequencies
and proportions. Comparisons of continuous patient
characteristics among the three diagnostic groups (RA,
PsA, AS) were performed by analysis of variance
(ANOVA) or Kruskal–Wallis test, according to data
distribution. Categorical variables were compared using
the chi-square test.
The effect of TNF-α inhibitors therapy on lipid profile
was assessed by comparing the levels of lipid particles at
each time point with the baseline prior to treatment.
Each lipid particle was analyzed in univariable and multi-
variable models, adjusted for the following study parame-
ters: hyperlipidemia, statin treatment, steroid treatment,
rheumatic diseases (RA, PsA, AS), obesity, smoking, dia-
betes, hypertension, ischemic heart disease, gender, and
age.
Comparisons at various times were performed by
repeated-measures mixed-model ANOVA. This proced-
ure takes into account the intracorrelation of repeated
measurements carried out on the same subject and does
not exclude subjects with incomplete data at follow-up.
Stratification analysis by statin use was employed in a
multivariable model in patients treated concomitantly
with a TNF-α inhibitor and statins after adjustment for
hyperlipidemia, hypertension, obesity, gender, and age.
The analyses were conducted with the PASW (SPSS)
19 statistical package (PASW Software Statistic, SPSS,
Chicago, IL, USA). All statistical tests were two-sided
and statistical significance was considered p ≤ 0.05.
Results
Study population
Of the 689 patients treated with TNF-α inhibitors be-
tween 2001 and 2011, 311 met the inclusion criteria: 152
RA patients, 90 PsA patients, and 69 AS patients. The
mean age of RA and PsA patients was higher (47.6 ± 19.3
and 50.2 ± 13.4 years, respectively) than that of AS pa-
tients (39.7 ± 15.2 years, p <0. 01). As expected, there were
more females in the RA group (74.3 %) than in the AS
group (36.0 %, p < 0.01). Corticosteroids were used more
often in the RA group (58.7 %) than in the PsA and AS
groups (29.2 % and 26.6 %, respectively, p < 0.01).
Diabetes, hyperlipidemia, and hypertension were more
prevalent in the PsA group (19.0 %, p = 0.03; 52.2 %, p =
0.02; and 40.0 %, p = 0.02, respectively) than in the RA
group (11.2 %, 37.5 %, and 36.2 %, respectively) and the
AS group (1.4 %, 32.0 %, and 20.3 %, respectively). The in-
cidence of ischemic heart disease did not differ signifi-
cantly between the groups. Smoking was more prevalent
in the AS group (45.0 %, p = 0.02) than in the RA and PsA
groups (26.3 % and 30.0 %, respectively). Baseline values
of TC and LDL did not differ significantly between the
groups. HDL and TG levels were significantly lower in
patients with AS. Higher TG levels were found in PsA
patients. There was no difference at baseline between
the three groups in the percentage of patients treated
with statins (Table 2). We excluded nine patients treated
with fibrates from the TG group. These nine patients were
treated with a constant dose of fibrates throughout the
study and exhibited no significant changes in HDL and
LDL values when TNF-α inhibitor was introduced; they
were included in the TC, HDL, and LDL analysis.
Lipid profile
TC and TG levels increased following TNF-α inhibitor
treatment, mainly during the first 6 months of treatment,
and decreased thereafter but remained significantly higher
than baseline at last follow-up (Table 3). LDL and HDL
levels did not change significantly following introduction
of TNF-α inhibitors.
The same pattern was found in the multivariate model
after adjustment for hyperlipidemia, statin treatment, ster-
oid treatment, rheumatic diseases (RA, PsA, AS), obesity,
smoking, diabetes, hypertension, ischemic heart disease,
gender, and age.
Atherogenic index
The AI increased significantly following TNF-α inhibitor
treatment (Table 3). The same increase was found in the
multivariate model after adjustment for hyperlipidemia,
statin treatment, steroid treatment, rheumatic diseases
(RA, PsA, AS), obesity, smoking, diabetes, hypertension,
ischemic heart disease, gender, and age.
Co-administration of TNF-α inhibitors and statins
The effect of the interaction between TNF-α inhibitors
and statins on the various lipid parameters after adjustment
for hyperlipidemia, hypertension, obesity, gender, and
age reached statistical significance for LDL (p < 0.01),
TC (p = 0.02), and TG (p < 0.01) values (Table 4). No ef-
fect of the interaction was found in HDL values and
therefore data were not analyzed further.
LDL levels rose higher than baseline values (103.13 ±
3.68 mg/dl) in patients treated with TNF-α inhibitors
but not with statins, reaching statistical significance at
12–18 months (106.85 ± 3.80 mg/dl, p = 0.024) and
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18–24 months (107.70 ± 3.76 mg/dl, p = 0.001). LDL in
patients who began statins after the initiation of TNF-α
inhibitors reached peak value at 6 months and 12–18
months. In contrast, LDL decreased significantly in pa-
tients who were treated with statins before starting TNF-α
inhibitors and continued throughout the study: from
119.97 ± 2.86 mg/dl at baseline to 107.84 ± 3.96 mg/dl
at 0–6 months (p < 0.01), 108.26 ± 4.07 mg/dl at 6–12
months (p < 0.01), 101.85 ± 3.57 mg/dl at 12–18 months
(p < 0.01), and 104.02 ± 3.57 mg/dl at 18–24 months (p <
0.01) (Table 4).
TC increased in patients not treated with TNF-α in-
hibitors or statins, from 183.73 ± 3.26 mg/dl at baseline
to 188.63 ± 3.42 mg/dl at 0–6 months (p < 0.01) and
187.77 ± 3.22 mg/dl at 12–18 months (p = 0.03). In
patients who began statins after the initiation of TNF-α
inhibitors, TC increased from 188.96 ± 8.92 mg/dl at
baseline to 208.22 ± 9.02 mg/dl at 0–6 months (p < 0.01),
198.55 ± 9.15 mg/dl at 12–18 months (p = 0.04), and
199.38 ± 8.46 mg/dl at 18–24 months (p = 0.01). TC values
in patients treated with statins before initiation of TNF-α
inhibitors did not change significantly.
The same pattern was observed in TG values, which
increased significantly in patients treated with TNF-α
inhibitors but not statins, and in patients who began
statins after the initiation of TNF-α inhibitors, but only
in the first 6 months. TG values increased, but not sig-
nificantly, in patients treated with statins before TNF-α
inhibitor initiation and during the whole study period
(Table 4).
Table 2 Baseline characteristics of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis p value
(n = 152) (n = 90) (n = 69)
Age (years) 47.6 ± 19.3 50.2 ± 13.4 39.7 ± 15.2 <0.0001
50.0 52.0 38
Baseline (mg/dl) TCa,b 180.6 ± 37.6 186.4 ± 35.2 174.3 ± 38.9 NS
183.0 185.0 172.0
HDLa,c 53.92 ± 15.67 51.23 ± 14.51 46.40 ± 13.31 0.003
52.08 48.25 43.38
LDLa,d 108.77 ± 25.63 114.43 ± 22.31 111.67 ± 34.09 NS
110.70 117.14 109.39
TGa,e 111.35 ± 53.44 128.36 ± 57.32 109.49 ± 53.87 0.04
96.46 119.00 106.00
Gender Male 39 (25.7) 26 (28.9) 44 (64.0) <0.0001
Female 113 (74.3) 64 (71.1) 25 (36.0)
Statin treatment Treated before and during treatment
with TNF-α inhibitors
25 (18.4) 22 (24.4) 9 (13.0) NS
Began treatment after beginning
TNF-α inhibitors treatment
18 (11.8) 11 (12.2) 8 (11.6)
Medication Classical DMARDsf 93 (62.0) 35 (39.3) 20 (31.3) <0.0001
Steroids 88 (58.7) 26 (29.2) 17 (26.6) <0.0001
Smoking Current or past 40 (26.3) 27 (30.0) 31 (44.9) 0.02
Obesity 27 (17.8) 22 (24.4) 6 (8.7) 0.04
Hyperlipidemia 57 (37.5) 47 (52.2) 22 (32.0) 0.02
Diabetes 17 (11.2) 17 (18.9) 1 (1.4) 0.003
Hypertension 55 (36.2) 36 (40.0) 14 (20.3) 0.02
Ischemic heart disease 21 (13.8) 7 (7.8) 4 (5.8) NS
Data presented as standard deviation with median below, or as n (%)
aBecause of missing values of lipid profile at various time points, the number of patients for each lipid profile test differed
bTC: 152 RA, 90 PsA, and 69 AS patients
cHDL: 113 RA, 74 PsA, and 46 AS patients
dLDL: 122RA, 73 PsA, and 50 AS patients
eTG: 120 RA, 71 PsA, and 49 AS patients
fClassical DMARDs: leflunomide, azathioprine, cyclosporin, mercaptopurine, methotrexate, hydroxychloroquine, sulfasalazine
TC total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein, TG, triglycerides, TNF-α tumor necrosis factor alpha, DMARD disease-modifying
anti-rheumatic drug, RA rheumatoid arthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, NS not significant
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Discussion
The demographic and clinical characteristics of our co-
hort are consistent with those described in the literature.
AS patients were young and most were males, while RA
patients were older, needed more treatment with cortico-
steroids, and most were females [20, 21]. A large meta-
analysis by Armstrong et al. in 2013 [22] showed an in-
creased risk of metabolic syndrome in patients with psor-
iasis (odds ratio 2.26). According to our data, diabetes,
hyperlipidemia, and hypertension were more prevalent in
PsA patients than in RA and AS patients (Table 2).
TNF-α inhibitors revolutionized the treatment of in-
flammatory arthritic conditions [23, 24]. In our study,
TNF-α inhibitors significantly increased the AI, TC, and
TG levels without significantly changing LDL and HDL
levels. They also significantly increased LDL, TC, and
TG levels in patients who were not treated with statins
during the study. This was in contrast to the decrease in
LDL levels in patients who were treated with statins
prior to initiation of TNF-α inhibitors and continued
treatment throughout the study.
A comparison of our results with those reported in the
literature must take into account the different study de-
signs. The 15 studies that assessed the effects of TNF-α
inhibitors on lipid profile (Table 1) [3–17] were of
shorter duration, ranging from 2 to 30 weeks in nine
studies [4, 6–8, 10–12, 15, 17] and up to 52 weeks in six
other studies [3, 5, 9, 13, 14, 16]. Follow-up in our study
was 104 weeks. We conducted our analysis on pooled
data of rheumatic patients in the ASPARA cohort while
most of the published studies analyzed a single disease:
12 studies of RA, one study of PsA, and one study of
AS. Sample size also varied: 15–80 patients in published
studies [4, 6–13, 16, 17] compared with 311 patients in
our cohort. Six of the studies were performed in patients
treated with infliximab (INF) alone, and the rest included
data on different types of TNF-α inhibitors such as INF,
etanercept (ETA), and/or adalimumab (ADA) (11 of 15
studies) [3, 4, 6–13, 15, 17]. Our study was performed in
patients treated with INF, ETA, or ADA.
Our finding of a significant increase in TC levels follow-
ing TNF-α inhibitor treatment (Table 3) is in line with the
results of 10 of the 15 studies mentioned [3–11, 14]. Six of
the 15 studies also reported an increase in TG levels follow-
ing TNF-α inhibitors [3, 5, 9, 11, 12, 14], similar to our find-
ings, while the other nine showed no significant changes in
TG levels. Nine of the 15 studies studied the effect of TNF-
α inhibitors on the AI [3, 5, 7–9, 11, 13, 14, 17]. Only one
of them showed an increase in the AI [9], similar to our
results, while the others did not demonstrate significant




0–6 months 6–12 months 12–18 months 18–24 months
Total cholesterol (mg/dl) Mean ± standard error 180.85 ± 2.12 188.12 ± 2.35 183.80 ± 2.14 184.48 ± 2.08 184.88 ± 2.09
p value <0.0001 NS 0.030 0.015
Multivariate modela
p value
0.018 NS 0.041 0.018
HDL (mg/dl) Mean ± standard error 51.8 ± 1.07 53.55 ± 1.21 51.06 ± 1.13 52.04 ± 1.18 52.05 ± 1.18
p value NS NS NS NS
Multivariate modela
p value
NS NS NS NS
LDL (mg/dl) Mean ± standard error 108.70 ± 1.55 109.00 ± 1.92 108.42 ± 1.76 108.54 ± 1.75 108.67 ± 1.70
p value NS NS NS NS
Multivariate modela
p value
NS NS NS NS
Triglycerides (mg/dl) Mean ± standard error 116.00 ± 3.55 132.02 ± 4.63 124.47 ± 3.95 128.72 ± 4.17 129.36 ± 4.32
p value <0.0001 0.005 <0.0001 <0.0001
Multivariate modela
p value
<0.0001 0.004 <0.0001 <0.0001
Atherogenic index (LogTG/HDL) Mean ± standard error –0.032 ± 0.017 –0.001 ± 0.02 –0.01 ± 0.019 0.009 ± 0.018 0.004 ± 0.019
p value 0.005 0.043 0.001 0.003
Multivariate modela
p value
0.007 0.04 0.001 0.004
aAdjusted for hyperlipidemia, statin treatment, steroid treatment, rheumatic diseases (RA, AS, PsA), obesity, smoking, diabetes, hypertension, ischemic heart
disease, gender, and age
TNF-α tumor necrosis factor alpha, HDL high-density lipoprotein, LDL low-density lipoprotein, TG, triglycerides, NS not significant, RA rheumatoid arthritis,
AS ankylosing spondylitis, PsA psoriatic arthritis
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changes of the AI. Concomitant treatment with statins,
known to reduce TG, TC, LDL, and TNF-α levels [25, 26],
could account for the lack of increase in TG levels and
consequently the AI in those studies. Three studies
that showed an increase in TG values included pa-
tients on drugs that affect the lipid profile, such as sta-
tins [5, 9, 12]; the studies that did not show significant
changes in TG levels did not include them in their cal-
culations [4, 6–8, 10, 13, 15, 16].
Our results showed no significant changes in the HDL
and LDL values following TNF-α inhibitor treatment.
The 10 studies from the literature [3–8, 10, 11, 14, 17]
(Table 1) that did report increased levels of HDL could
be explained by the longer follow-up period in our study.
Wijbrandts et al. [16] reported a significant increase in
HDL levels after 16 weeks of ADA treatment, although
the level returned to baseline by the end of the 52-week
study. Similarly, HDL levels in our study increased dur-
ing the first 24 weeks and returned to near baseline
levels later, although none of these changes was statisti-
cally significant (Table 3). Like in our cohort, nine of the
15 studies that assessed the effects of TNF-α inhibitors
on lipid profile [3, 4, 7, 9, 12, 14–17] showed no signifi-
cant change in LDL level following TNF-α inhibitor
treatment. Because this could be due to concomitant
treatment with statins, which can lower LDL values
[25, 26], we tested whether there was an interaction
between TNF-α inhibitor and statin treatment that af-
fected the lipid profile.
LDL, TG, and TC levels increased significantly in pa-
tients treated with TNF-α inhibitors but not with statins.
LDL and TC levels also increased significantly in pa-
tients who began statin therapy during the study, while
TG increased significantly only during the first 6 months
in this group. LDL values in patients treated with statins
before and during the entire study period decreased sig-
nificantly throughout the study. Thus, concomitant
treatment with TNF-α inhibitor and statins may protect
against the expected increase in LDL, helping reduce the
cardiovascular risk in rheumatic patients in addition to
treating the inflammatory component.
To our knowledge, no other study has demonstrated
the benefit to LDL levels of adding statin treatment to
TNF-α inhibitors. A meta-analysis of 31 observational
studies showed that the TNF-α gene is involved in the
pathogenesis of the metabolic syndrome (the 308A vari-
ant of this gene has been associated with elevated levels
of insulin and blood pressure) [27]. Another study re-
ported an association between polymorphisms of TNF-α
(TNF-αG-238A) and LDL level [28]. These investigators
also found that TNF-α-C-857T—a polymorphism of the
TNF-α gene promoter that increases transcription—is
associated with increased LDL values and the formation
of atherosclerotic carotid plaques in type 2 diabetes pa-
tients. Carriers of TNF-α-C-857T had significantly in-
creased LDL values compared with noncarriers. There
was no difference in LDL values in patients who were
not treated with statins regardless of the carrier state of
Table 4 Effects of TNF-α inhibitor treatment on lipid profile: stratification analysis by statin use
No statins Statin treatment begun after
initiating TNF-α inhibitor
treatment
Statin treatment begun before and
continued during TNF-α inhibitor
treatment
Time period Mean ± standard error p value Mean ± standard error p value Mean ± standard error p value
Total cholesterola (mg/dl) Reference 183.73 ± 3.26 188.96 ± 8.92 182.04 ± 5.65
0–6 months 188.63 ± 3.42 0.007 208.22 ± 9.02 0.005 188.78 ± 5.73 NS
6–12 months 185.20 ± 3.29 NS 197.92 ± 8.74 NS 184.05 ± 5.60 NS
12–18 months 187.77 ± 3.22 0.03 198.55 ± 9.15 0.04 180.42 ± 5.48 NS
18–24 months 188.62 ± 3.34 NS 199.38 ± 8.46 0.01 178.89 ± 5.14 NS
LDLa (mg/dl) Reference 103.13 ± 3.68 112.10 ± 5.62 119.97 ± 2.86
0–6 months 106.01 ± 3.83 0.057 123.42 ± 7.62 0.05 107.84 ± 3.96 <0.001
6–12 months 105.63 ± 3.80 NS 115.35 ± 7.05 NS 108.26 ± 4.07 <0.001
12–18 months 106.85 ± 3.80 0.02 119.67 ± 6.38 0.03 101.85 ± 3.57 <0.001
18–24 months 107.70 ± 3.76 0.001 115.89 ± 6.81 NS 104.02 ± 3.57 <0.001
Triglyceridesa (mg/dl) Reference 119.41 ± 9.75 179.31 ± 19.96 142.14 ± 9.89
0–6 months 134.33 ± 10.24 <0.001 223.91 ± 24.84 0.002 147.33 ± 10.67 NS
6–12 months 128.80 ± 10.05 0.02 186.09 ± 20.47 NS 145.81 ± 10.15 NS
12–18 months 135.89 ± 10.19 0.001 181.31 ± 20.98 NS 149.60 ± 10.16 NS
18–24 months 135.99 ± 10.20 <0.001 194.68 ± 23.42 NS 146.72 ± 10.82 NS
aAdjusted for hyperlipidemia, hypertension, obesity, gender, and age
TNF-α tumor necrosis factor alpha, LDL low-density lipoprotein, NS not significant
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TNF-α-C-857T. In contrast, carriers of TNF-α-C-857T
who were treated with statins had increased LDL levels
compared with noncarriers [29]. In other words, there is
a link between statin therapy, TNF-α activity level, and
LDL. These findings, together with our results, call for
further research into the impact on LDL levels of adding
statin treatment in patients with increased activity levels
of TNF-α (as in carriers who harbor the TNF-α-C-857T
polymorphism) compared with patients with low activity
levels of TNF-α (such as those receiving TNF-α inhibitors).
There are some limitations in our study. In addition to
being a retrospective and observational study without a
control group, the study was conducted on a relatively
small cohort of patients which included those who were
taking various medications, including steroids and fibrates,
and had illnesses such as diabetes that could affect lipid
metabolism. We dealt with this limitation by constructing
statistical models for each lipid profile parameter adjusted
for possible confounders (Tables 3 and 4). Being a retro-
spective study, follow-up data were not complete on all
subjects; nevertheless, in order to include them in the ana-
lyses, we used repeated measures with mixed models that
allow for unbalanced data and calculated the intracor-
relation of repeated measurements carried out on the
same subject. We estimated the drug intake according
to pharma dispensed prescriptions. It would be interest-
ing to evaluate the effects of long-term anti-TNF ther-
apy on carotid artery US findings and its association
with lipid profiles changes in further studies.
Conclusions
The study documents the real-life, long-term follow-up
and treatment of RA, PsA, and AS patients being treated
with TNF-α inhibitors. We found that this treatment pro-
motes an atherogenic lipid profile most pronounced in pa-
tients not treated by statins, evidenced by a significant
increase in the AI, LDL, TC, and TG levels. Statin therapy
before and during treatment with TNF-α inhibitors may
protect against the expected rise in LDL values. While
there were negative changes in the lipid profile under
TNF-α inhibitor treatment, they were relatively small and
not statistically significant, and their clinical significance is
unclear.
Coronary disease is the main cause of death in rheum-
atic diseases and the importance of reducing cardiovascu-
lar risk factors, including dyslipidemia, in these patients
cannot be overemphasized. Prospective studies on the
long-term effects of TNF-α inhibitors on lipid profile, with
and without statins, are required to assess the cardiovas-
cular risk in these patients.
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